X-Cor Therapeutics: Reducing intubation for respiratory failure
X-Cor Therapeutics has a novel hybrid cartridge that removes CO2 from patients’ blood through procedures that are less invasive than high-flow alternatives for respiratory failure. Company officials think their technology could reduce the need for intubation since X-Cor uses a hybrid approach that allows patients’ blood to be drawn at less than 300 ml/min flows through small catheters placed by nursing staff.
The company reported in February to the SEC that it had raised a little over $200,000.
You may also like: